JP2016502527A5 - - Google Patents

Download PDF

Info

Publication number
JP2016502527A5
JP2016502527A5 JP2015542832A JP2015542832A JP2016502527A5 JP 2016502527 A5 JP2016502527 A5 JP 2016502527A5 JP 2015542832 A JP2015542832 A JP 2015542832A JP 2015542832 A JP2015542832 A JP 2015542832A JP 2016502527 A5 JP2016502527 A5 JP 2016502527A5
Authority
JP
Japan
Prior art keywords
mir
hsa
composition
mirna
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015542832A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016502527A (ja
JP6478916B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/070350 external-priority patent/WO2014078686A1/en
Publication of JP2016502527A publication Critical patent/JP2016502527A/ja
Publication of JP2016502527A5 publication Critical patent/JP2016502527A5/ja
Application granted granted Critical
Publication of JP6478916B2 publication Critical patent/JP6478916B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015542832A 2012-11-16 2013-11-15 薬物耐性乳癌の予後判定および処置のための治療アジュバントおよびバイオマーカーとしてのｍｉＲＮＡ Expired - Fee Related JP6478916B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261727481P 2012-11-16 2012-11-16
US61/727,481 2012-11-16
PCT/US2013/070350 WO2014078686A1 (en) 2012-11-16 2013-11-15 Mirnas as novel therapeutic adjuvants and biomarkers for the prognosis and treatment of drug resistant breast cancers

Publications (3)

Publication Number Publication Date
JP2016502527A JP2016502527A (ja) 2016-01-28
JP2016502527A5 true JP2016502527A5 (cg-RX-API-DMAC7.html) 2016-12-28
JP6478916B2 JP6478916B2 (ja) 2019-03-06

Family

ID=50731724

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015542832A Expired - Fee Related JP6478916B2 (ja) 2012-11-16 2013-11-15 薬物耐性乳癌の予後判定および処置のための治療アジュバントおよびバイオマーカーとしてのｍｉＲＮＡ

Country Status (6)

Country Link
US (2) US9730954B2 (cg-RX-API-DMAC7.html)
EP (1) EP2919817A4 (cg-RX-API-DMAC7.html)
JP (1) JP6478916B2 (cg-RX-API-DMAC7.html)
CN (1) CN104884097B (cg-RX-API-DMAC7.html)
CA (1) CA2930795A1 (cg-RX-API-DMAC7.html)
WO (1) WO2014078686A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2686313C2 (ru) 2015-02-25 2019-04-25 Байонир Корпорейшн Фармацевтическая композиция для лечения рака, содержащая микроРНК в качестве активного ингредиента
CN106148538B (zh) * 2016-08-09 2019-10-22 山东大学 microRNA标志物组及其在制备评价乳腺癌化疗敏感性试剂盒中的应用
CN107970254A (zh) * 2017-12-08 2018-05-01 新乡医学院第附属医院 miR-204及其靶基因在诊断和治疗骨肉瘤中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102533966B (zh) * 2005-08-01 2014-03-12 俄亥俄州立大学研究基金会 用于乳腺癌的诊断、预后和治疗的基于MicroRNA的方法和组合物
EP2250496A4 (en) * 2008-02-28 2011-08-31 Univ Ohio State Res Found MICRO-RNA SIGNATURES ASSOCIATED WITH CYTOGENETICS AND PROGNOSIS IN ACUTE MYELOID LEUKEMIA (AML) AND USES THEREOF
WO2009137660A2 (en) * 2008-05-07 2009-11-12 Abraxis Bioscience, Llc Enhancement of drug therapy by mirna
EP2354246A1 (en) 2010-02-05 2011-08-10 febit holding GmbH miRNA in the diagnosis of ovarian cancer

Similar Documents

Publication Publication Date Title
AU2018233032B2 (en) TEC family kinase inhibitor adjuvant therapy
Li et al. Stem cell quiescence
Yi et al. A Hybrid Nanoadjuvant Simultaneously Depresses PD‐L1/TGF‐β1 and Activates cGAS‐STING Pathway to Overcome Radio‐Immunotherapy Resistance
Khandelwal et al. Ruxolitinib as salvage therapy in steroid-refractory acute graft-versus-host disease in pediatric hematopoietic stem cell transplant patients
Radich et al. HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen
Hu et al. Nanodrugs incorporating LDHA siRNA inhibit M2-like polarization of TAMs and amplify autophagy to assist oxaliplatin chemotherapy against colorectal cancer
KR20160066554A (ko) 브루톤 타이로신 키나제 억제제 및 면역요법을 이용한 치료
CN110934873B (zh) 靶向组织微环境中衰老细胞的抗衰老药物d/s及其应用
Toro et al. New therapeutic perspectives in the treatment of uveal melanoma: a systematic review
Carew et al. Oncolytic reovirus inhibits angiogenesis through induction of CXCL10/IP-10 and abrogation of HIF activity in soft tissue sarcomas
CN106488766A (zh) 利用氧气疗法的分割放疗和化疗
AU2020322440A2 (en) Compositions and methods of using C/EBP alpha saRNA
Jin et al. Different origin-derived exosomes and their clinical advantages in cancer therapy
Zhou et al. Tellurium/bovine serum albumin nanocomposites inducing the formation of stress granules in a protein kinase R-dependent manner
Synoradzki et al. From molecular biology to novel immunotherapies and nanomedicine in uveal melanoma
Luca et al. Morphological, genetic and clinical correlations in infantile hemangiomas and their mimics
JP2016502527A5 (cg-RX-API-DMAC7.html)
JP2009510165A5 (cg-RX-API-DMAC7.html)
Farhangfar et al. In vivo study of anticancer activity of ginsenoside Rh2-containing arginine-reduced graphene in a mouse model of breast cancer
Zhou et al. Circular RNA-regulated autophagy is involved in cancer progression
Pan et al. Cudraflavone B induces human glioblastoma cells apoptosis via ER stress-induced autophagy
CN111905101A (zh) 一种cd47抗体联合il-6细胞因子药在肿瘤治疗中的应用及验证其治疗肿瘤的方法
Huang et al. Preconditioning chemotherapy with paclitaxel and cisplatin enhances the antitumor activity of cytokine induced‐killer cells in a murine lung carcinoma model
US20200199681A1 (en) Mda-7 cancer therapies and methods of detecting biomolecules
Cai et al. Plasma Extracellular Vesicle‐Derived miR‐296‐5p is a Maturation‐Dependent Rejuvenation Factor that Downregulates Inflammation and Improves Survival after Sepsis